Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 7, Issue 5, Pages 426-437Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd2462
Keywords
-
Funding
- Intramural NIH HHS [Z01 MH002828-05, Z01 MH002857-03] Funding Source: Medline
- NIMH NIH HHS [K02 MH076222, K02MH076222] Funding Source: Medline
Ask authors/readers for more resources
Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available